Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Videos|July 14, 2015
Important Differences in Treatment Guidelines for Dyslipidemia
Karen J. McConnell, PharmD, FCCP, BCPS, describes differences in treatment for dyslipidemia.
Advertisement
Karen J. McConnell, PharmD, FCCP, BCPS, clinical pharmacy specialist in cardiology at the Kaiser Permanente of Colorado and associate professor at the Skaggs School of Pharmacy (University of Colorado), describes differences in treatment for dyslipidemia.
This video was recorded at APhA’s Annual Meeting and Exposition in March 2015.
Advertisement
Related to this article
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Ramantamig's 93.6% ORR and Outpatient CRS Control
3
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
4
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
5